Hardisty C A, Fowles A, Munro D S
Clin Endocrinol (Oxf). 1984 May;20(5):597-605. doi: 10.1111/j.1365-2265.1984.tb00109.x.
Over a three year period we have studied the effect of either a one year course of Carbimazole or a single dose of radioiodine in a group of 46 patients with Graves' disease. Initially, in untreated patients LATS-P was present in 39 (85%) but at the end of the study was only detectable in 19 (41%). The clinical outcome in 29 patients initially treated with carbimazole correlated well with changes in serum LATS-P which persisted in 18. Thirteen of these ultimately required radioiodine or sub-total thyroidectomy. With radioiodine two patterns of response were seen, in some LATS-P levels declined, whereas in others transient increases were seen usually during the first year but subsequently fell. There was no difference in clinical response between the two groups. Overall, the study indicates that serum LATS-P is related to the clinical course of Graves' disease but there remains a minority of patients in whom the activity cannot be detected.
在三年的时间里，我们研究了一组46例格雷夫斯病患者接受为期一年的卡比马唑治疗或单次放射性碘治疗的效果。最初，未经治疗的患者中39例（85%）存在长效甲状腺刺激素保护物（LATS-P），但在研究结束时，仅19例（41%）可检测到。最初接受卡比马唑治疗的29例患者的临床结果与血清LATS-P的变化密切相关，其中18例LATS-P持续存在。这些患者中有13例最终需要放射性碘治疗或甲状腺次全切除术。放射性碘治疗出现两种反应模式，一些患者的LATS-P水平下降，而另一些患者通常在第一年出现短暂升高，但随后下降。两组的临床反应没有差异。总体而言，该研究表明血清LATS-P与格雷夫斯病的临床病程有关，但仍有少数患者无法检测到其活性。
